NasdaqGS:AMED - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2,702	173	N/A	N/A	2
12/31/2025	2,515	167	166	196	10
12/31/2024	2,354	126	170	176	9
6/30/2024	2,290	92	88	96	N/A
3/31/2024	2,251	-21	91	105	N/A
12/31/2023	2,236	-10	124	137	N/A
9/30/2023	2,228	3	105	118	N/A
6/30/2023	2,229	2	101	114	N/A
3/31/2023	2,234	112	103	111	N/A
12/31/2022	2,223	119	126	133	N/A
9/30/2022	2,220	121	91	98	N/A
6/30/2022	2,216	140	166	173	N/A
3/31/2022	2,222	191	177	184	N/A
12/31/2021	2,214	209	182	189	N/A
9/30/2021	2,206	220	242	250	N/A
6/30/2021	2,196	247	264	271	N/A
3/31/2021	2,117	202	331	337	N/A
12/31/2020	2,072	184	284	289	N/A
9/30/2020	2,021	166	294	298	N/A
6/30/2020	1,972	128	256	263	N/A
3/31/2020	1,980	127	180	188	N/A
12/31/2019	1,956	127	194	202	N/A
9/30/2019	1,889	127	184	191	N/A
6/30/2019	1,812	124	204	212	N/A
3/31/2019	1,731	123	197	203	N/A
12/31/2018	1,663	119	217	223	N/A
9/30/2018	1,626	88	184	192	N/A
6/30/2018	1,583	71	128	133	N/A
3/31/2018	1,546	42	N/A	119	N/A
12/31/2017	1,511	30	N/A	106	N/A
9/30/2017	1,474	43	N/A	102	N/A
6/30/2017	1,456	40	N/A	99	N/A
3/31/2017	1,438	46	N/A	77	N/A
12/31/2016	1,419	37	N/A	62	N/A
9/30/2016	1,391	41	N/A	54	N/A
6/30/2016	1,358	38	N/A	78	N/A
3/31/2016	1,313	38	N/A	106	N/A
12/31/2015	1,266	-3	N/A	108	N/A
9/30/2015	1,230	-7	N/A	92	N/A
6/30/2015	1,204	-7	N/A	87	N/A
3/31/2015	1,193	-10	N/A	-45	N/A
12/31/2014	1,188	13	N/A	-66	N/A
9/30/2014	1,191	-4	N/A	-62	N/A
6/30/2014	1,192	-103	N/A	-59	N/A
3/31/2014	1,203	-109	N/A	64	N/A
12/31/2013	1,233	-93	N/A	102	N/A
9/30/2013	1,278	-191	N/A	109	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AMEDの予測収益成長率 (年間24.6% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: AMEDの収益 ( 24.6% ) はUS市場 ( 15% ) よりも速いペースで成長すると予測されています。

高成長収益: AMEDの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: AMEDの収益 ( 5.8% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: AMEDの収益 ( 5.8% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AMEDの自己資本利益率は、3年後には低くなると予測されています ( 12.5 %)。

Amedisys 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 54%

Price target decreased by 8.5% to US$98.85

Consensus EPS estimates fall by 16%

Price target decreased to US$126

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Consensus EPS estimates fall by 11%

Recent updates

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS misses analyst expectations

Insufficient new directors

President notifies of intention to sell stock

Consensus EPS estimates fall by 54%

Third quarter 2023 earnings: EPS misses analyst expectations

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Investor sentiment improves as stock rises 19%

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Price target decreased by 8.5% to US$98.85

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 41% Discount?

Does Amedisys (NASDAQ:AMED) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS exceeds analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys (NASDAQ:AMED) Will Be Hoping To Turn Its Returns On Capital Around

Chairman & CEO exercised options and sold US$221k worth of stock

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

At US$83.54, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

A Look At The Fair Value Of Amedisys, Inc. (NASDAQ:AMED)

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

High number of new directors

Capital Allocation Trends At Amedisys (NASDAQ:AMED) Aren't Ideal

Consensus EPS estimates fall by 16%

Price target decreased to US$126

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Is Now The Time To Look At Buying Amedisys, Inc. (NASDAQ:AMED)?

An Intrinsic Calculation For Amedisys, Inc. (NASDAQ:AMED) Suggests It's 38% Undervalued

Amedisys: ROIC, Tangible Book Value Each Softening

Consensus EPS estimates fall by 11%

Slowing Rates Of Return At Amedisys (NASDAQ:AMED) Leave Little Room For Excitement

Price target decreased to US$145

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Amedisys profit beats by $0.24, revenue misses by $25.23M, 2022 guidance below estimates

We Think Amedisys (NASDAQ:AMED) Can Stay On Top Of Its Debt

Price target decreased to US$160

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

At US$115, Is It Time To Put Amedisys, Inc. (NASDAQ:AMED) On Your Watch List?

Price target decreased to US$174

Returns On Capital At Amedisys (NASDAQ:AMED) Have Stalled

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Is Amedisys, Inc. (NASDAQ:AMED) Trading At A 40% Discount?

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Does Amedisys (NASDAQ:AMED) Deserve A Spot On Your Watchlist?

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

Price target decreased to US$184

Chairman & CEO exercised options and sold US$2.8m worth of stock

Full year 2021 earnings: EPS misses analyst expectations

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Is Amedisys (NASDAQ:AMED) A Risky Investment?

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Amedisys (NASDAQ:AMED) Shareholders Will Want The ROCE Trajectory To Continue

High number of new directors

Investor sentiment improved over the past week

Lead Independent Director recently bought US$141k worth of stock

Should You Be Adding Amedisys (NASDAQ:AMED) To Your Watchlist Today?